• “cannabis-based product for medicinal use in humans” means a preparation or other product, other than one to which paragraph 5 of part 1 of Schedule 4 applies, which—

  1. a

     is or contains cannabis, cannabis resin, cannabinol or a cannabinol derivative (not being dronabinol or its stereoisomers);

  2. b

     is produced for medicinal use in humans; and—

  3. c

     is—

     1. i

        a medicinal product, or

     2. ii

        a substance or preparation for use as an ingredient of, or in the production of an ingredient of, a medicinal product;

• “clinical trial” has the same meaning as in the Medicines for Human Use (Clinical Trials) Regulations 20046;

• “dronabinol” does not include any substance which—

  1. a

     has the international non-proprietary name dronabinol (recommended by the World Health Organisation); and

  2. b

     is derived from cannabis, cannabis resin or their constituents,

  and stereoisomers of dronabinol are to be construed accordingly;; and

• “medicinal product” has the same meaning as in the Human Medicines Regulations 20127;